What is HC Wainwright’s Estimate for BCYC Q1 Earnings?

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) – Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Bicycle Therapeutics in a research report issued to clients and investors on Friday, October 31st. HC Wainwright analyst S. Ramakanth expects that the company will post earnings per share of ($1.06) for the quarter. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.06) per share. HC Wainwright also issued estimates for Bicycle Therapeutics’ Q2 2026 earnings at ($1.08) EPS, Q3 2026 earnings at ($1.10) EPS and Q4 2026 earnings at ($1.14) EPS.

Other equities analysts have also issued reports about the company. Morgan Stanley lowered their target price on Bicycle Therapeutics from $17.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 12th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $11.00 target price (down from $27.00) on shares of Bicycle Therapeutics in a research report on Friday. Citigroup restated an “outperform” rating on shares of Bicycle Therapeutics in a report on Friday. JMP Securities set a $12.00 price objective on shares of Bicycle Therapeutics in a report on Friday. Finally, Oppenheimer restated an “outperform” rating and issued a $44.00 target price (down previously from $48.00) on shares of Bicycle Therapeutics in a report on Monday, August 11th. Seven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.80.

Bicycle Therapeutics Stock Down 10.0%

Bicycle Therapeutics stock opened at $7.26 on Monday. Bicycle Therapeutics has a 12-month low of $6.10 and a 12-month high of $25.39. The firm’s fifty day moving average is $7.66 and its 200 day moving average is $7.87. The company has a market capitalization of $503.19 million, a PE ratio of -2.01 and a beta of 1.48.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Friday, August 8th. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.19). The company had revenue of $2.90 million during the quarter, compared to analyst estimates of $9.43 million. Bicycle Therapeutics had a negative return on equity of 36.05% and a negative net margin of 884.51%.

Institutional Trading of Bicycle Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Personalized Indexing Management LLC purchased a new stake in Bicycle Therapeutics during the 3rd quarter valued at $100,000. State of Tennessee Department of Treasury purchased a new stake in Bicycle Therapeutics during the 2nd quarter valued at $100,000. Soleus Capital Management L.P. purchased a new stake in Bicycle Therapeutics during the 2nd quarter valued at $695,000. Monimus Capital Management LP purchased a new stake in shares of Bicycle Therapeutics during the second quarter worth about $592,000. Finally, Rangeley Capital LLC purchased a new stake in shares of Bicycle Therapeutics during the second quarter worth about $521,000. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Kevin Lee sold 3,231 shares of the business’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $8.41, for a total transaction of $27,172.71. Following the completion of the transaction, the chief executive officer directly owned 475,310 shares in the company, valued at $3,997,357.10. The trade was a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 8,527 shares of company stock worth $71,738 over the last three months. 8.50% of the stock is currently owned by insiders.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.